Company Profile

Hubei Tianshu Pharmaceutical Co.,Ltd.

• 150,000 _m² Covers an Area
• 2 Production Workshops
• 255 _m³ Production Capacity

• Corporate Promotional Video

Committed to become an outstanding global supplier of APIs and advanced intermediates,as well as a comprehensive solution service provider

Nanjing Vcare Subsidiary Manufacturing Base

Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) was jointly established in 2022 by Yicheng Tianshu Textile and Vcare Pharmatech with shared capital investment. It's located in  Jingxi Huagong Industrial Park Yicheng, covering an area of 150,000 square meters. Tianshu Pharmaceutical is committed to becoming a globally leading CDMO for innovative drugs, a supplier of high-end active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates, as well as a comprehensive solution provider. Its product pipeline spans multiple therapeutic areas, including contrast medias, cardiovascular diseases, diabetes, antivirals, immune system disorders, and neurological conditions.

Guided by its mission to "create value for customers, leverage differentiated technologies, advanced manufacturing, and ensure robust quality systems," Tianshu Pharmaceutical upholds innovation as its driving force. It achieves industrialized production of pharmaceuticals with high technical barriers and continuous multi-step complex processes. Simultaneously, the company actively explores advanced engineering technologies in the biomedicine field—such as continuous flow, micro-packed beds, metal catalysis, and enzymatic catalysis—to develop greener, safer, and more intelligent solutions. This enables Tianshu Pharmaceutical to consistently provide customers with more efficient, high-quality, and cost-effective products and services.

Tianshu Pharmaceutical’s facility design and construction strictly adhere to relevant guidelines and standards including EU GMP, FDA, and ICH requirements, ensuring compliance with high-end client audit and registration demands. The first phase of the project commenced production in July 2023, with capacity including one API production workshop and one intermediate production workshop. The API workshop has a built-up area of 2,000 m², equipped with 34 reactors and a total capacity of approximately 55 m³. The intermediate workshop covers 3,000 m² and includes 9 production lines (including one hydrogenation line), outfitted with 71 reactors of various specifications—from 100 L to 5,000 L—including enamel-lined reactors as well as high-temperature, cryogenic, and hydrogenation reactors, with a total capacity of about 200 m³. The planning and design of the proposed third and fourth workshops are currently underway.